Miconia sp. Increases mRNA Levels of PPAR Gamma and Inhibits Alpha Amylase and Alpha Glucosidase

Abstract

Diabetes mellitus is a public health problem worldwide. For this reason, ethanolic extract of Miconia sp. from Oaxaca, Mexico, was selected in search of an alternative against this disease. The effect of Miconia sp. on mRNA expression of PPARγ on cell line 3T3-L1, its effect on alpha amylase and alpha glucosidase, lipid accumulation during adipogenesis, and cell viability on VERO cells were evaluated. The mRNA levels of PPARγ increased on 1.393 ± 0.008 folds, lipid accumulation was increased by 29.55% with Miconia sp. extract and 34.57% with rosiglitazone, and α-amylase and α-glycosidase were inhibited with IC50 values from 28.23 ± 2.15 μg/mL and 1.95 ± 0.15 μg/mL, respectively; the IC50 on antiproliferative activity on VERO cells was 314.54 ± 45.40 μg/mL. In case of α-amylase and α-glycosidase assays, IC50 (inhibitory concentration 50) refers to necessary extract amounts to inhibit 50% of enzymatic activity. On the other hand, on antiproliferative activity, IC50 (inhibitory concentration 50) refers to necessary extract amounts to inhibit 50% of cell proliferation. It was concluded that the compounds present in Miconia sp. ethanolic extract increase mRNA expression of PPARγ, inhibit α-amylase and α-glucosidase, and increase lipid accumulation. It constitutes an alternative as adjuvant in diabetes mellitus treatment; therefore, we recommend continuing identifying the compounds responsible for its promising in vivo antidiabetic activity.

Antioxidant Activity and Inhibitory Potential ofCistus salviifolius(L.) andCistus monspeliensis(L.) Aerial Parts Extracts against Key Enzymes Linked to Hyperglycemia

“…Our finding is in accordance with earlier reports that showed that some medicinal plant extracts have more potent α -glucosidase inhibitory activities than powerful synthetics inhibitors such as acarbose [32–34]. Also, the results are in line with a study performed on another species of Cistus genus ( Cistus laurifolius L.) that showed that ethanolic extract of this plant is a potent inhibitor of α -glucosidase (IC 50 = 6.3  μ g/mL) and has a remarkable and dose-dependent inhibitory effect on α -amylase and also improves hyperglycemia in type 2 diabetic rats [35].…”

Pharmacological investigation ofAjuga ivaessential oils collected at three phenological stages

“…At the best of our knowledge, there are any study carried out on antidiabetic effects of AIEO. Furthermore, our findings are in line with previous studies that have proven that some medicinal plants have more potent inhibitory activities than the reference compound such as acarbose 37,38 . Moreover, our results are in agreement with other studies that found that the aqueous extract of A iva decreased blood glucose levels in diabetic rats compared to the control group 39,40 .…”

GC-MS Analysis and Inhibitory Evaluation of Terminalia catappa Leaf Extracts on Major Enzymes Linked to Diabetes

“…Nonetheless, this potential was more portrayed in α -amylase activity as T. catappa leaf extracts exhibited a better inhibitory potential than acarbose. This was corroborated by various studies that have previously reported a higher inhibitory potential of medicinal plant extracts than acarbose [16, 18, 19]. It was also noteworthy that our extracts had better α -glucosidase and α -amylase inhibitory activities than those reported for Nicotiana tabacum and Calotropis procera leaf extracts [20, 21].…”